Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Topics

Semaglutide · GLP-1 receptor agonist · Major adverse cardiovascular events (MACE) · Heart failure · Heart failure with preserved ejection fraction · Heart failure with reduced ejection fraction · Atherosclerotic cardiovascular disease · Obesity · Overweight · Cardiovascular death · All-Cause Mortality · Heart failure hospitalization · Non-fatal myocardial infarction · Non-fatal stroke · SELECT trial · Randomized controlled trial · Double-blind randomized controlled trial · Body mass index · Subcutaneous administration · Drug Titration · New York Heart Association functional class · Diuretic Therapy · Secondary analysis · Hazard ratio · Composite Endpoint · Serious adverse events · Ejection fraction classification · Weight management · Cardiometabolic risk · Clinical trial registration